GILEAD SCIENCES INC (NASDAQ: GILD)

GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

最近更新时间: 25 Nov, 6:10PM

90.49

0.30 (0.33%)

加入群组

前收盘价格	90.19
收盘价格	90.93
成交量	10,641,237
平均成交量 (3个月)	6,668,701
市值	112,774,963,200

市盈率 (P/E TTM)	1,005.44
预期市盈率 (P/E Forward)	12.22
价格/销量 (P/S)	4.06
股市价格/股市净资产 (P/B)	6.21

52周波幅	62.07 (-31%) — 98.90 (9%)
利润日期	4 Feb 2025 - 10 Feb 2025
股息率 (DY TTM)	3.40%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看涨	看涨
	Drug Manufacturers - General (全球的)	看涨	看涨
股票	Gilead Sciences, Inc.	看涨	看涨

AIStockmoo 评分

-0.9

分析师共识	1.5
内部交易活动	-2.5
价格波动	-0.5
技术平均移动指标	-2.5
技术振荡指标	-0.5
平均	-0.90

相关股票

股票	市值	DY	P/E（TTM）	P/B
GILD	113 B	3.40%	1,005.44	6.21
AMGN	143 B	3.38%	34.01	18.81
AZN	240 B	1.93%	37.45	5.19
SNY	120 B	8.54%	25.24	1.55
GRFS	6 B	-	32.20	0.830
BIIB	23 B	-	14.35	1.31

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Value
内部持股比例	0.12%
机构持股比例	88.40%

52周波幅	62.07 (-31%) — 98.90 (9%)
目标价格波幅	80.00 (-11%) — 125.00 (38%)
高	125.00 (Citigroup, 38.14%)	购买
中	101.00 (11.62%)
低	80.00 (Cantor Fitzgerald, -11.59%)	保留
平均值	100.44 (11.00%)
总计	11 购买, 7 保留
平均价格@调整类型	93.61

公司	日期	目标价格	调整类型	价格@调整类型
Cantor Fitzgerald	11 Dec 2024	80.00 (-11.59%)	保留	92.38
Cantor Fitzgerald	07 Nov 2024	80.00 (-11.59%)	保留	97.90
RBC Capital	11 Dec 2024	84.00 (-7.17%)	保留	92.38
RBC Capital	18 Nov 2024	84.00 (-7.17%)	保留	88.46
B of A Securities	10 Dec 2024	109.00 (20.46%)	购买	92.34
Oppenheimer	10 Dec 2024	115.00 (27.09%)	购买	92.34
Oppenheimer	07 Nov 2024	105.00 (16.03%)	购买	97.90
Mizuho	21 Nov 2024	100.00 (10.51%)	购买	89.76
UBS	21 Nov 2024	96.00 (6.09%)	保留	89.76
Wolfe Research	15 Nov 2024	110.00 (21.56%)	购买	88.40
Citigroup	14 Nov 2024	125.00 (38.14%)	购买	92.11
Truist Securities	08 Nov 2024	97.00 (7.19%)	保留	96.57
BMO Capital	07 Nov 2024	102.00 (12.72%)	购买	97.90
BMO Capital	17 Oct 2024	94.00 (3.88%)	购买	87.36
Baird	07 Nov 2024	95.00 (4.98%)	保留	97.90
Barclays	07 Nov 2024	95.00 (4.98%)	保留	97.90
Barclays	07 Oct 2024	84.00 (-7.17%)	保留	84.43
Goldman Sachs	07 Nov 2024	84.00 (-7.17%)	保留	97.90
JP Morgan	07 Nov 2024	105.00 (16.03%)	购买	97.90
JP Morgan	09 Oct 2024	100.00 (10.51%)	购买	86.14
Piper Sandler	07 Nov 2024	105.00 (16.03%)	购买	97.90
Wells Fargo	07 Nov 2024	105.00 (16.03%)	购买	97.90
Wells Fargo	07 Oct 2024	100.00 (10.51%)	购买	84.43
Leerink Partners	21 Oct 2024	96.00 (6.09%)	购买	86.29
Bernstein	17 Oct 2024	105.00 (16.03%)	购买	87.36
显示更多

名称	平均购买 ($)	平均卖出 ($)	总净额	总净值 ($)
DICKINSON ANDREW D	-	92.34	-1,686	-155,685
MERCIER JOHANNA	-	92.34	-1,739	-160,579
O'DAY DANIEL PATRICK	-	92.34	-4,762	-439,723
PARSEY MERDAD	-	92.34	-1,771	-163,534
PATTERSON SANDRA	-	92.10	-565	-52,097
TELMAN DEBORAH H	-	92.34	-306	-28,256
累积净数量				-10,829
累积净值 ($)				-999,875
累积平均购买 ($)				-
累积平均卖出 ($)				92.27

名称	持有人	日期	类型	数量	价格	价值 ($)
PATTERSON SANDRA	职员	13 Dec 2024	处理 (-)	157	91.86	14,422
PATTERSON SANDRA	职员	13 Dec 2024	执行期权	157	-	-
DICKINSON ANDREW D	职员	10 Dec 2024	处理 (-)	1,686	92.34	155,685
DICKINSON ANDREW D	职员	10 Dec 2024	执行期权	3,640	-	-
MERCIER JOHANNA	职员	10 Dec 2024	处理 (-)	1,739	92.34	160,579
MERCIER JOHANNA	职员	10 Dec 2024	执行期权	3,752	-	-
O'DAY DANIEL PATRICK	职员	10 Dec 2024	处理 (-)	4,762	92.34	439,723
O'DAY DANIEL PATRICK	职员	10 Dec 2024	执行期权	10,295	-	-
PARSEY MERDAD	职员	10 Dec 2024	处理 (-)	1,771	92.34	163,534
PARSEY MERDAD	职员	10 Dec 2024	执行期权	3,820	-	-
TELMAN DEBORAH H	职员	10 Dec 2024	处理 (-)	306	92.34	28,256
TELMAN DEBORAH H	职员	10 Dec 2024	执行期权	639	-	-
PATTERSON SANDRA	职员	10 Dec 2024	处理 (-)	408	92.34	37,675
PATTERSON SANDRA	职员	10 Dec 2024	执行期权	901	-	-
显示更多

日期	类型	细节
17 Dec 2024	公告	U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
17 Dec 2024	公告	Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
13 Dec 2024	公告	Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
12 Dec 2024	公告	Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
09 Dec 2024	公告	Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
09 Dec 2024	公告	Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
08 Dec 2024	公告	Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
03 Dec 2024	公告	Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
27 Nov 2024	公告	Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
15 Nov 2024	公告	Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
13 Nov 2024	公告	Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
13 Nov 2024	公告	Gilead Prices $3.5 Billion of Senior Unsecured Notes
12 Nov 2024	公告	Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
08 Nov 2024	公告	Gilead Sciences to Present at Upcoming Investor Engagements
07 Nov 2024	公告	Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
06 Nov 2024	公告	Gilead Sciences Announces Third Quarter 2024 Financial Results
05 Nov 2024	公告	Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
31 Oct 2024	公告	AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
22 Oct 2024	公告	Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
19 Oct 2024	公告	Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
09 Oct 2024	公告	Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
09 Oct 2024	公告	Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
07 Oct 2024	公告	Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
02 Oct 2024	公告	Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
02 Oct 2024	公告	Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
显示更多

股息率 (DY TTM)	3.40%
5年平均股息收益率	3.91%
股息支付比率	3,400.00%
预计下次股息支付	Mar 2025

除息日	公告日期	支付日期	详情
13 Dec 2024	30 Oct 2024	30 Dec 2024	0.77 现金
13 Sep 2024	30 Jul 2024	27 Sep 2024	0.77 现金
14 Jun 2024	23 Apr 2024	27 Jun 2024	0.77 现金
14 Mar 2024	01 Feb 2024	28 Mar 2024	0.77 现金
14 Dec 2023	01 Nov 2023	28 Dec 2023	0.75 现金
14 Sep 2023	25 Jul 2023	28 Sep 2023	0.75 现金
14 Jun 2023	25 Apr 2023	29 Jun 2023	0.75 现金
14 Mar 2023	25 Jan 2023	30 Mar 2023	0.75 现金
14 Dec 2022	25 Oct 2022	29 Dec 2022	0.73 现金
14 Sep 2022	25 Jul 2022	29 Sep 2022	0.73 现金
14 Jun 2022	27 Apr 2022	29 Jun 2022	0.73 现金
14 Mar 2022	28 Jan 2022	30 Mar 2022	0.73 现金
14 Dec 2021	26 Oct 2021	30 Dec 2021	0.71 现金
14 Sep 2021	26 Jul 2021	29 Sep 2021	0.71 现金
14 Jun 2021	27 Apr 2021	29 Jun 2021	0.71 现金
12 Mar 2021	02 Feb 2021	30 Mar 2021	0.71 现金
14 Dec 2020	26 Oct 2020	30 Dec 2020	0.68 现金
14 Sep 2020	29 Jul 2020	29 Sep 2020	0.68 现金
11 Jun 2020	29 Apr 2020	29 Jun 2020	0.68 现金
12 Mar 2020	03 Feb 2020	30 Mar 2020	0.68 现金
12 Dec 2019	23 Oct 2019	30 Dec 2019	0.63 现金
12 Sep 2019	29 Jul 2019	27 Sep 2019	0.63 现金
13 Jun 2019	01 May 2019	27 Jun 2019	0.63 现金
14 Mar 2019	01 Feb 2019	28 Mar 2019	0.63 现金
13 Dec 2018	24 Oct 2018	28 Dec 2018	0.57 现金
13 Sep 2018	24 Jul 2018	27 Sep 2018	0.57 现金
14 Jun 2018	30 Apr 2018	28 Jun 2018	0.57 现金
15 Mar 2018	05 Feb 2018	29 Mar 2018	0.57 现金
14 Dec 2017	25 Oct 2017	28 Dec 2017	0.52 现金
14 Sep 2017	25 Jul 2017	28 Sep 2017	0.52 现金
14 Jun 2017	01 May 2017	29 Jun 2017	0.52 现金
14 Mar 2017	06 Feb 2017	30 Mar 2017	0.52 现金
13 Dec 2016	31 Oct 2016	29 Dec 2016	0.47 现金
14 Sep 2016	22 Jul 2016	29 Sep 2016	0.47 现金
14 Jun 2016	27 Apr 2016	29 Jun 2016	0.47 现金
14 Mar 2016	02 Feb 2016	30 Mar 2016	0.43 现金
14 Dec 2015	26 Oct 2015	30 Dec 2015	0.43 现金
14 Sep 2015	23 Jul 2015	29 Sep 2015	0.43 现金
12 Jun 2015	24 Apr 2015	29 Jun 2015	0.43 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2024	3.08	4	3.40
2023	3.00	4	3.70
2022	2.92	4	3.40
2021	2.84	4	3.91
2020	2.72	4	4.67
2019	2.52	4	3.88
2018	2.28	4	3.65
2017	2.08	4	2.90
2016	1.84	4	2.57
2015	1.29	3	1.28
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2024	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	0.44%
营业利益率 (TTM)	41.96%
稀释每股收益 (EPS TTM)	0.090
季度收入增长率 (YOY)	7.00%
季度盈利增长率 (YOY)	-42.50%

总债务/股东权益 (D/E MRQ)	126.42%
流动比率 (MRQ)	1.26
营业现金流 (OCF TTM)	10.02 B
杠杆自由现金流 (LFCF TTM)	9.08 B

资产报酬率 (ROA TTM)	11.96%
股东权益报酬率 (ROE TTM)	0.56%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)